{"id":1104,"date":"2025-10-16T12:50:01","date_gmt":"2025-10-16T12:50:01","guid":{"rendered":"https:\/\/leyton.majjane.agency\/se\/insights\/articles\/the-tax-incentive-youre-missing-how-leyton-sweden-helps-pharma-unlock-critical-rd-funding\/"},"modified":"2025-10-16T12:50:01","modified_gmt":"2025-10-16T12:50:01","slug":"the-tax-incentive-youre-missing-how-leyton-sweden-helps-pharma-unlock-critical-rd-funding","status":"publish","type":"article","link":"https:\/\/leyton.com\/se\/en\/insights\/articles\/the-tax-incentive-youre-missing-how-leyton-sweden-helps-pharma-unlock-critical-rd-funding\/","title":{"rendered":"The Tax Incentive You\u2019re Missing: How Leyton Sweden Helps Pharma Unlock Critical R&D Funding"},"content":{"rendered":"\n

Sweden has long been recognized as one of the most innovative nations in the world, with a pharmaceutical sector that delivers global impact well beyond its scale. According to Statistics Sweden, the industry invested 13,6 billion SEK of its own funds into research in 2023, with a total investment of 18,1 billion SEK when including external funding1<\/sup>.<\/p>\n\n\n\n

These investments are crucial not only for advancing science but also for maintaining Sweden\u2019s competitiveness and economic growth. With the government\u2019s latest national investment in research and innovation, placing a strong emphasis on commercialization2<\/sup>, there has never been a better time for pharmaceutical companies to optimize their funding opportunities. Yet, many companies are still leaving significant savings untapped by not fully leveraging R&D tax incentives.<\/p>\n\n\n\n

A sector dominated by small but ambitious players<\/h2>\n\n\n\n

While global names are part of the Swedish pharmaceutical landscape, the sector is fundamentally composed of small and micro-sized companies:<\/p>\n\n\n\n